Estás usando un navegador no soportado
Usar Internet Explorer está desaconsejado por problemas de seguridad. Para ver correctamente esta web, por favor use cualquier navegador moderno: Chrome, Firefox, Edge, Safari u otro de su elección.
En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias
FILTRAR POR:
374 ARTÍCULOS , VIENDO DEL 31 AL 45
Alzheimer's Disease and Natural Products: Future Regimens Emerging from Nature
Islam MA, Khandker SS, Alam F, Khalil MI, Kamal MA, Gan SH.
Curr Top Med Chem. 2017;17(12):1408-1428. doi: 10.2174/1568026617666170103163054.
Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends
Bachurin SO, Bovina EV, Ustyugov AA.
Med Res Rev. 2017 Sep;37(5):1186-1225. doi: 10.1002/med.21434. Epub 2017 Jan 13.
Chronoinflammaging in Alzheimer; A systematic review on the roles of toll like receptor 2
Ravari A, Mirzaei T, Kennedy D, Kazemi Arababadi M.
Life Sci. 2017 Feb 15;171:16-20. doi: 10.1016/j.lfs.2017.01.003. Epub 2017 Jan 11.
Synaptic Plasticity, Dementia and Alzheimer Disease
Skaper SD, Facci L, Zusso M, Giusti P.
CNS Neurol Disord Drug Targets. 2017;16(3):220-233. doi: 10.2174/1871527316666170113120853.
The Amyloid Cascade Hypothesis in Alzheimer's Disease: It's Time to Change Our Mind
Ricciarelli R, Fedele E.
Curr Neuropharmacol. 2017;15(6):926-935. doi: 10.2174/1570159X15666170116143743.
Update on Alzheimer's Disease Therapy and Prevention Strategies
Graham WV, Bonito-Oliva A, Sakmar TP.
Annu Rev Med. 2017 Jan 14;68:413-430. doi: 10.1146/annurev-med-042915-103753.
Management of Alzheimer's disease-An insight of the enzymatic and other novel potential targets
Islam BU, Tabrez S.
Int J Biol Macromol. 2017 Apr;97:700-709. doi: 10.1016/j.ijbiomac.2017.01.076. Epub 2017 Jan 19.
Reisberg B, Shao Y, Golomb J, Monteiro I, Torossian C, Boksay I, Shulman M, Heller S, Zhu Z, Atif A, Sidhu J, Vedvyas A, Kenowsky S.
Dement Geriatr Cogn Disord. 2017;43(1-2):100-117. doi: 10.1159/000455397. Epub 2017 Jan 26.
Behavioural effects of novel multitarget anticholinesterasic derivatives in Alzheimer's disease
Giménez-Llort L, Ratia M, Pérez B, Camps P, Muñoz-Torrero D, Badia A, Clos MV.
Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):124-131. doi: 10.1097/FBP.0000000000000292.
Wu WY, Dai YC, Li NG, Dong ZX, Gu T, Shi ZH, Xue X, Tang YP, Duan JA.
J Enzyme Inhib Med Chem. 2017 Dec;32(1):572-587. doi: 10.1080/14756366.2016.1210139.
Sreenivasmurthy SG, Liu JY, Song JX, Yang CB, Malampati S, Wang ZY, Huang YY, Li M.
Int J Mol Sci. 2017 Jan 28;18(2):272. doi: 10.3390/ijms18020272.
Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease
Chase TN, Farlow MR, Clarence-Smith K.
Neurotherapeutics. 2017 Apr;14(2):405-416. doi: 10.1007/s13311-016-0511-x.
Therapeutic potentials of herbal drugs for Alzheimer’s disease—An overview
Kumar A, Singh A, Aggarwal A.
Indian J Exp Biol. 2017 Feb;55(2):63-73.
Potential benefits of phytochemicals against Alzheimer's disease
Wightman EL.
Proc Nutr Soc. 2017 May;76(2):106-112. doi: 10.1017/S0029665116002962. Epub 2017 Feb 1.
Exploration of Various Proteins for the Treatment of Alzheimer's Disease
Islam BU, Zaidi SK, Kamal MA, Tabrez S.
Curr Drug Metab. 2017;18(9):808-813. doi: 10.2174/1389200218666170203110135.
Actualización mensual Regístrese para recibir los avisos de actualización
Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.